HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.
Stocks · News reference
Legend Biotech Reports 50% Of CARTITUDE-2 Patients Remained Progression-Free At 5 Years After Single CARVYKTI Infusion
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMMBRIDGEWATER, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Legend Biotech
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Legend Biotech Appoints Ingrid Zhang As CEO; Succeeds Alan Bash.
'Legend Naming Novartis Executive as CEO' - Wall Street Journal
https://www.wsj.com/health/pharma/legend-naming-novartis-executive-as-ceo-6a79fa0c